Janssen BV, Oteman B, Ali M, Valkema PA, Adsay V, Basturk O, Chatterjee D, Chou A, Crobach S, Doukas M, Drillenburg P, Esposito I, Gill AJ, Hong SM, Jansen C, Kliffen M, Mittal A, Samra J, van Velthuysen MF, Yavas A, Kazemier G, Verheij J, Steyerberg E, Besselink MG, Wang Het al.(2024) Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improvement and Validation Study Am J Surg Pathol, 48(9), 1108-1116 DOI 10.1097/PAS.0000000000002270, PubMed 38985503
Farnes I, Lund-Iversen M, Aabakken L, Verbeke C, Labori KJ(2024) Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced pancreatic cancer - real world data from the NORPACT-2 study Scand J Gastroenterol, 59(9), 1093-1096 DOI 10.1080/00365521.2024.2373115, PubMed 38957079
Stoop TF, Oba A, Wu YHA, Beaty LE, Colborn KL, Janssen BV, Al-Musawi MH, Franco SR, Sugawara T, Franklin O, Jain A, Saiura A, Sauvanet A, Coppola A, Javed AA, Groot Koerkamp B, Miller BN, Mack CE, Hashimoto D, Caputo D, Kleive D, Sereni E, Belfiori G, Ichida H, van Dam JLet al.(2024) Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy JAMA Netw Open, 7(6), e2417625 DOI 10.1001/jamanetworkopen.2024.17625, PubMed 38888920